GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Total Equity

NervGen Pharma (TSXV:NGEN) Total Equity : C$9.18 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Total Equity?

NervGen Pharma's total equity for the quarter that ended in Sep. 2024 was C$9.18 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

NervGen Pharma Total Equity Historical Data

The historical data trend for NervGen Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Total Equity Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial 5.84 5.92 16.82 13.46 -2.01

NervGen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.11 -2.01 18.83 12.49 9.18

NervGen Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

NervGen Pharma's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=13.236-15.245
=-2.01

NervGen Pharma's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=22.459-13.28
=9.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma Total Equity Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Total Equity
Comparable Companies
XCNQ:DTC TSX:EPRX TSX:BCT NEOE:MMED XCNQ:MSET TSX:ONC TSXV:ARCH TSXV:MIR TSXV:DMT TSX:HBP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
NGENF:USA 9UA:Germany
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
Website
https://www.nervgen.com
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.
Executives
John Ruffolo Director
Krista Mckerracher Director
William Joseph Radvak Director
Harold Punnett 10% Security Holder, Director
Robert Pilz Senior Officer

NervGen Pharma Headlines

No Headlines